vs

Side-by-side financial comparison of Almonty Industries Inc. (ALM) and Relay Therapeutics, Inc. (RLAY). Click either name above to swap in a different company.

Relay Therapeutics, Inc. is the larger business by last-quarter revenue ($7.0M vs $6.3M, roughly 1.1× Almonty Industries Inc.).

Almonty Industries Inc. is an international mining company primarily engaged in the extraction and development of tungsten resources. The company operates in Spain, Portugal, and South Korea and is publicly traded on the Toronto Stock Exchange (TSX). The current Chief Executive Officer is Lewis Black.

Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.

ALM vs RLAY — Head-to-Head

Bigger by revenue
RLAY
RLAY
1.1× larger
RLAY
$7.0M
$6.3M
ALM

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ALM
ALM
RLAY
RLAY
Revenue
$6.3M
$7.0M
Net Profit
$-5.4M
Gross Margin
Operating Margin
Net Margin
-86.1%
Revenue YoY
Net Profit YoY
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALM
ALM
RLAY
RLAY
Q4 25
$7.0M
Q3 25
$6.3M
$0
Q2 25
$7.2M
Q1 25
$7.7M
Q4 24
$0
Q3 24
$0
Q2 24
$0
Q1 24
$10.0M
Net Profit
ALM
ALM
RLAY
RLAY
Q4 25
Q3 25
$-5.4M
$-74.1M
Q2 25
$-58.2M
Q1 25
$-77.1M
Q4 24
Q3 24
$-88.1M
Q2 24
$-92.2M
Q1 24
$-81.4M
Operating Margin
ALM
ALM
RLAY
RLAY
Q4 25
Q3 25
Q2 25
Q1 25
-1105.2%
Q4 24
Q3 24
Q2 24
Q1 24
-903.0%
Net Margin
ALM
ALM
RLAY
RLAY
Q4 25
Q3 25
-86.1%
Q2 25
-809.4%
Q1 25
-1003.6%
Q4 24
Q3 24
Q2 24
Q1 24
-813.3%
EPS (diluted)
ALM
ALM
RLAY
RLAY
Q4 25
Q3 25
$-0.43
Q2 25
Q1 25
$-0.46
Q4 24
Q3 24
$-0.63
Q2 24
$-0.69
Q1 24
$-0.62

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALM
ALM
RLAY
RLAY
Cash + ST InvestmentsLiquidity on hand
$84.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$567.1M
Total Assets
$621.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALM
ALM
RLAY
RLAY
Q4 25
$84.0M
Q3 25
$91.6M
Q2 25
Q1 25
$93.5M
Q4 24
$124.3M
Q3 24
$152.4M
Q2 24
$134.1M
Q1 24
$152.9M
Stockholders' Equity
ALM
ALM
RLAY
RLAY
Q4 25
$567.1M
Q3 25
$607.7M
Q2 25
Q1 25
$721.1M
Q4 24
$777.8M
Q3 24
$838.9M
Q2 24
$681.7M
Q1 24
$745.8M
Total Assets
ALM
ALM
RLAY
RLAY
Q4 25
$621.3M
Q3 25
$670.0M
Q2 25
Q1 25
$799.4M
Q4 24
$871.3M
Q3 24
$930.1M
Q2 24
$772.5M
Q1 24
$841.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALM
ALM
RLAY
RLAY
Operating Cash FlowLast quarter
$-235.5M
Free Cash FlowOCF − Capex
$-235.9M
FCF MarginFCF / Revenue
-3370.0%
Capex IntensityCapex / Revenue
5.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-622.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALM
ALM
RLAY
RLAY
Q4 25
$-235.5M
Q3 25
$-62.1M
Q2 25
Q1 25
$-73.2M
Q4 24
$-249.1M
Q3 24
$-75.1M
Q2 24
$-65.8M
Q1 24
$-50.3M
Free Cash Flow
ALM
ALM
RLAY
RLAY
Q4 25
$-235.9M
Q3 25
$-62.1M
Q2 25
Q1 25
$-73.6M
Q4 24
$-251.1M
Q3 24
$-75.3M
Q2 24
$-65.8M
Q1 24
$-52.1M
FCF Margin
ALM
ALM
RLAY
RLAY
Q4 25
-3370.0%
Q3 25
Q2 25
Q1 25
-958.4%
Q4 24
Q3 24
Q2 24
Q1 24
-520.7%
Capex Intensity
ALM
ALM
RLAY
RLAY
Q4 25
5.9%
Q3 25
Q2 25
Q1 25
5.0%
Q4 24
Q3 24
Q2 24
Q1 24
17.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons